Research programme: obesity therapeutics - Unigene
Alternative Names: Anorexigenic peptide - Unigene; UGL 269; UGP-281Latest Information Update: 04 Nov 2017
At a glance
- Originator Unigene Laboratories
- Class Peptides
- Mechanism of Action Amylin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Obesity
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA (PO, Capsule)
- 22 May 2012 Pharmacodynamics data from preclinical trials released by Unigene
- 28 Jun 2011 Final pharmacodynamics data from preclinical trials in Obesity presented at the 71st Annual Scientific Sessions of the American Diabetes Assocation (ADA-2011)